



# Change of Adviser

November 6, 2020

RNS Number : 4449E

Renalytix AI PLC

06 November 2020

**Renalytix AI plc**  
("RenalytixAI" or the "Company")

## Change of adviser

**NEW YORK, November 6, 2020** - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the appointment of Investec Bank plc as joint corporate broker, with immediate effect to work alongside its existing nominated adviser and joint broker, Stifel.

*For further information, please contact:*

**Renalytix AI plc**

James McCullough, CEO

[www.renalytixai.com](http://www.renalytixai.com)

**Via Walbrook PR**

**Stifel (Nominated Adviser, Joint Broker)**

Alex Price / Nicholas Moore

**Tel: 020 7710 7600**

**Investec Bank plc (Joint Broker)**

Gary Clarence / Daniel Adams

**Tel: 020 7597 4000**

**Walbrook PR Limited**

Paul McManus / Lianne Cawthorne

**Tel: 020 7933 8780** or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)

**Mob: 07980 541 893 / 07584 391 303**

## About Kidney Disease

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37

million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD\*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

\* <https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html>

#### **About RenalytixAI**

RenalytixAI is a developer of artificial intelligence-enabled clinical *in vitro* diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit [www.renalytixai.com](http://www.renalytixai.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPFSLFAIESSESF